Last updated 27 days ago

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

500 patients around the world

Available in Argentina, United States

Pfizer

7Research sites

500Patients around the world

This study is for people with

Breast Cancer

Requirements for the patient

From 18 Years

All Gender

Medical requirements

Sites

Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires

Recruiting

Viamonte 2278, CABA, Buenos Aireswww.cinme.com.ar

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Recruiting

Av. Pueyrredon 1746, CABA, Buenos Aireshttp://www.ciprec.org/es

Organización Médica de Investigación (OMI)

Recruiting

Uruguay 725 PB , Buenos Aires, CP: 1015

Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja

Recruiting

Dorrego 269, La Rioja

Sanatorio Norte SRL - Santiago del Estero

Recruiting

25 De Mayo 138, Santiago del Estero

Fundación Respirar

Recruiting

Av. Cabildo 1548, CABA, Buenos Aires

Fundación CENIT para la Investigación en Neurociencias

Recruiting

Juncal 2222, C1125 CABA, Argentina

SponsorPfizer

Conditions

Breast Cancer

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06105632